CC
CDTX

Callan Capital’s Cidara Therapeutics CDTX Stock Holding History

Callan Capital’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,758
Closed -$87.6K – 317
2024
Q1 		$87.6K Sell
4,758
-415
-8% -$5.96K 0.01% 292
2023
Q4 		$82.1K Hold
5,173
– – 0.01% 226
2023
Q3 		$97.5K Hold
5,173
– – 0.01% 196
2023
Q2 		$117K Hold
5,173
– – 0.01% 177
2023
Q1 		$131K Hold
5,173
– – 0.02% 176
2022
Q4 		$78.2K Buy
+5,173
New +$61.7K 0.01% 182
2016
Q3 		– Sell
-593
Closed -$122K – 51
2016
Q2 		$122K Buy
+593
New +$144K 0.05% 64

Other funds holding CDTX

MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $390M AUM 96.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Callan Capital's CDTX Position: Q2 2024 in Review

Callan Capital sold out of Cidara Therapeutics (CDTX) in Q2 2024, closing a stake of 4,758 shares — an estimated $87.6K sold.

Callan Capital first reported a position in CDTX in Q2 2016 and held it in 7 quarters. The position peaked at $131K in Q1 2023. 26 funds tracked by Wall St. Rank hold CDTX as of Q2 2024.

  • Callan Capital reported no remaining Cidara Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Callan Capital sold 4,758 Cidara Therapeutics shares in Q2 2024, an estimated $87.6K.
  • Callan Capital first reported a position in Cidara Therapeutics in Q2 2016 and held it in 7 quarters.
  • Callan Capital's Cidara Therapeutics position peaked at $131K in Q1 2023.
  • 26 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2024.

Based on Callan Capital's 13F filing for Q2 2024, filed 12 Aug 2024.